NDAORALTABLETPriority Review
Approved
Apr 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRECATOR (ethionamide) is an oral small-molecule antibiotic approved in 1965 for treatment of tuberculosis, particularly drug-resistant TB. It works by inhibiting mycolic acid synthesis in Mycobacterium tuberculosis, disrupting bacterial cell wall formation. The drug is typically used as a second-line or adjunctive agent in multidrug-resistant TB regimens.
LOE Approaching
This is a legacy product approaching LOE with minimal ongoing commercial investment; team sizes are likely small and focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis
Started Mar 2026
64 enrolled
Tuberculosis Meningitis
Pharmacokinetics of Ethionamide and Ethionamide Sulfoxide in Patients Established on Treatment for Tuberculosis.
Started Jun 2022
30 enrolled
Tuberculosis, Pulmonary
Career Relevance
TRECATOR offers limited career growth potential as a legacy product in LOE phase with zero linked job postings. Roles available are primarily in stewardship, compliance, and access—not brand building or commercial expansion. This is suitable only for specialists in TB, global health, or legacy product management seeking niche expertise.
Worked on TRECATOR at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.